Mercer Global Advisors’s ProQR Therapeutics PRQR Stock Holding History

Mercer Global Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86K	Buy	+1,000	New	+$1.65K	﹤0.01%	5608

Other funds holding PRQR

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Mercer Global Advisors's PRQR Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in ProQR Therapeutics (PRQR) in Q2 2026: 1,000 shares worth $1.86K. The stake represents ﹤0.01% of the portfolio and ranks #5608 among its holdings.

39 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Mercer Global Advisors held 1,000 shares of ProQR Therapeutics worth $1.86K as of Q2 2026.
ProQR Therapeutics was a new Mercer Global Advisors position in Q2 2026.
ProQR Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5608 holding.
39 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.